AXGN
Axogen Inc.

1,402
Mkt Cap
$1.6B
Volume
1.64M
52W High
$36.00
52W Low
$9.22
PE Ratio
-90.88
AXGN Fundamentals
Price
$30.78
Prev Close
$31.16
Open
$31.38
50D MA
$32.62
Beta
1.03
Avg. Volume
994,274.81
EPS (Annual)
-$0.341
P/B
11.28
Rev/Employee
$362,070.74
$1,529.33
Loading...
Loading...
News
all
press releases
AxoGen (NASDAQ:AXGN) Insider Sells $171,457.64 in Stock
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) insider Erick Wayne Devinney sold 5,221 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $32.84, for a total value of $171,457.64. Following the completion of the transaction...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Erick Wayne Devinney Sells 5,221 Shares of AxoGen (NASDAQ:AXGN) Stock
AxoGen, Inc. (NASDAQ:AXGN - Get Free Report) insider Erick Wayne Devinney sold 5,221 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price...
MarketBeat·4d ago
News Placeholder
Do Options Traders Know Something About Axogen Stock We Don't?
Investors need to pay close attention to AXGN stock based on the movements in the options market lately.
Zacks·5d ago
News Placeholder
AxoGen, Inc. $AXGN is First Light Asset Management LLC's Largest Position
First Light Asset Management LLC boosted its position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 28.2% in the third quarter, according to the company in its most recent 13F filing with...
MarketBeat·6d ago
News Placeholder
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
ArrowMark Colorado Holdings LLC grew its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 20.4% during the third quarter, according to the company in its most recent filing with the Securities...
MarketBeat·7d ago
News Placeholder
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen (NASDAQ:AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair...
MarketBeat·10d ago
News Placeholder
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+
AxoGen (NASDAQ:AXGN) executives outlined a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application...
MarketBeat·12d ago
News Placeholder
Royce & Associates LP Purchases New Shares in AxoGen, Inc. $AXGN
Royce & Associates LP acquired a new position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The...
MarketBeat·16d ago
News Placeholder
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
AxoGen (NASDAQ:AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected...
MarketBeat·17d ago
News Placeholder
AxoGen, Inc. $AXGN Shares Acquired by First Eagle Investment Management LLC
First Eagle Investment Management LLC grew its position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 142.7% during the 3rd quarter, according to the company in its most recent disclosure with the...
MarketBeat·18d ago
<
1
2
...
>

Latest AXGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.